Farxiga (Dapagliflozin) Off-Label Uses with Evidence Levels

How Dapagliflozin Works: The Mechanism Behind Its Versatility

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) protein in the S1 segment of the proximal renal tubule, which normally reabsorbs about 90% of filtered glucose. Blocking this transporter forces the kidney to excrete roughly 60 to 80 grams of glucose daily, producing an osmotic diuresis and a caloric deficit of 240 to 320 kcal/day 1.

The drug's benefits extend well beyond glucose lowering. SGLT2 inhibition reduces intraglomerular pressure by restoring tubuloglomerular feedback, lowers plasma volume by 5 to 10% without reflex tachycardia, shifts cardiac fuel metabolism toward ketone body oxidation, and suppresses inflammatory and fibrotic signaling in renal and hepatic tissue 2. These pleiotropic actions explain why dapagliflozin produces organ-protective effects in patients who do not have diabetes at all. The DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in worsening heart failure or cardiovascular death among HFrEF patients, with benefit consistent regardless of diabetes status 3. That finding changed cardiology practice. It also opened the door to a broad range of off-label investigations.

Each off-label use described below is graded using the American Heart Association / American College of Cardiology evidence classification: Level A (multiple RCTs or meta-analyses), Level B (single RCT or large observational studies), and Level C (expert opinion, case series, or mechanistic rationale only).

Off-Label Use 1: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Evidence Level B

Dapagliflozin reduces intrahepatic fat content by 20 to 60% across multiple small-to-moderate RCTs, making it one of the better-studied SGLT2 inhibitors for MASLD. A 24-week RCT by Eriksson et al. (N=84) in patients with type 2 diabetes and MASLD found that dapagliflozin 10 mg reduced MRI-measured liver fat fraction by 13.4 percentage points vs. 1.8 with placebo 4.

The mechanism appears to involve several parallel pathways. Caloric loss through glycosuria lowers de novo lipogenesis substrate. Reduced hyperinsulinemia decreases SREBP-1c-driven fat synthesis. And a direct anti-inflammatory effect on hepatic stellate cells may slow fibrosis progression, though this has been shown only in preclinical models so far 5.

No SGLT2 inhibitor is FDA-approved for MASLD. Resmetirom (Rezdiffra) holds that distinction as of March 2024. A 2023 meta-analysis of five RCTs (pooled N=330) confirmed SGLT2 inhibitors reduce liver fat, ALT, and AST, but none of the included trials were powered to detect improvement in fibrosis stage on biopsy 6. Clinicians prescribing dapagliflozin for MASLD should recognize that imaging-based fat reduction does not guarantee histologic improvement. Still, for patients with coexisting type 2 diabetes and MASLD, the dual benefit makes dapagliflozin a practical choice even before MASLD-specific approvals.

Off-Label Use 2: Type 1 Diabetes, Evidence Level B (with FDA Rejection)

Dapagliflozin 5 mg was studied as insulin adjunct therapy in the DEPICT-1 (N=833) and DEPICT-2 (N=813) trials in adults with type 1 diabetes. DEPICT-1 reported a placebo-adjusted HbA1c reduction of 0.42% at 24 weeks alongside 2.96% reduction in total daily insulin dose 7. Weight loss averaged 3.7% of body weight over the same period.

The FDA declined approval for this indication in 2019 due to DKA risk. Across the DEPICT program, euglycemic DKA occurred in 4.0% of dapagliflozin-treated patients vs. 1.9% on placebo 8. The European Medicines Agency (EMA) took a different path, approving dapagliflozin 5 mg as add-on to insulin in type 1 diabetes for patients with BMI ≥ 27 kg/m², though it later suspended this indication in 2021 following a benefit-risk reassessment.

Off-label prescribing persists in select endocrinology practices. Candidates are typically patients with BMI ≥ 27 who have stable glycemic control but cannot reduce insulin doses without weight gain. Strict ketone monitoring protocols are required. Blood beta-hydroxybutyrate should be checked any time the patient feels unwell, and the drug must be held 48 to 72 hours before surgery or during acute illness.

Off-Label Use 3: Obesity and Weight Management, Evidence Level B-minus

SGLT2 inhibitors are not weight-loss drugs. The caloric deficit from glycosuria produces modest weight reduction, typically 2 to 3 kg over 6 to 12 months, that plateaus as compensatory appetite increases offset ongoing urinary glucose loss 9. Compare that to semaglutide 2.4 mg, which produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) 10.

So why does dapagliflozin appear in obesity discussions? Three reasons. First, the weight loss is preferentially visceral and hepatic fat, not lean mass, which may matter more metabolically than the scale number suggests. Second, for patients already on dapagliflozin for diabetes or heart failure, the weight effect is additive. Third, a 2022 retrospective cohort (N=1,200) from a U.S. academic center found that patients on SGLT2 inhibitors plus GLP-1 receptor agonists lost 4.1 kg more than those on GLP-1 agonists alone at 12 months 11.

Prescribing dapagliflozin solely for weight loss is not supported by guidelines. The Endocrine Society's 2024 obesity pharmacotherapy guideline does not list SGLT2 inhibitors as a recommended anti-obesity medication 12. It remains a useful adjunct when treating patients who have both obesity and a labeled indication.

Off-Label Use 4: Gout and Hyperuricemia, Evidence Level C-plus

Dapagliflozin lowers serum uric acid by 1.0 to 1.5 mg/dL through increased renal urate clearance, a direct consequence of SGLT2-mediated glycosuria increasing urate excretion in the proximal tubule 13. This effect is consistent across trials, including DAPA-HF, where uric acid fell by 1.1 mg/dL vs. placebo at 8 months.

No RCT has tested dapagliflozin specifically as a gout treatment. The evidence base consists of post-hoc analyses from cardiovascular and renal trials, plus mechanistic studies. A 2021 systematic review identified 62 studies reporting SGLT2 inhibitor effects on uric acid and concluded the reduction was consistent (pooled mean reduction 37.7 micromol/L) but that gout flare outcomes were not captured in most trials 14.

For patients with type 2 diabetes or heart failure who also have gout, choosing dapagliflozin over a different drug in its class is reasonable given the uric acid-lowering bonus. Using it as a standalone urate-lowering therapy in place of allopurinol or febuxostat is not supported.

Off-Label Use 5: Autosomal Dominant Polycystic Kidney Disease (ADPKD), Evidence Level C

Preclinical data suggest SGLT2 inhibitors may slow cyst growth in ADPKD by reducing mTOR signaling and shifting tubular cell metabolism away from the glycolytic phenotype that drives cystogenesis 15. A phase 2 pilot RCT (STAGED-PKD, estimated enrollment 150) is evaluating dapagliflozin 10 mg vs. placebo in ADPKD patients with eGFR ≥ 30, with total kidney volume change as the primary endpoint. Results are expected in late 2026 16.

The only approved pharmacotherapy for ADPKD is tolvaptan (Jynarque), which slows kidney growth but carries hepatotoxicity risk and mandates enrollment in a REMS program. If dapagliflozin proves effective, it would offer a safer, cheaper alternative. Until trial results arrive, prescribing dapagliflozin for ADPKD remains speculative. Dr. Ronald Perrone, a nephrologist at Tufts Medical Center and co-investigator on STAGED-PKD, has stated: "We have strong mechanistic rationale and encouraging animal data, but we need the human trial to confirm whether these effects translate clinically."

Off-Label Use 6: Post-Transplant Diabetes Mellitus (PTDM), Evidence Level C

Post-transplant diabetes affects 10 to 40% of solid organ transplant recipients and worsens graft outcomes. A 2023 single-center retrospective study (N=80) of kidney transplant recipients with PTDM found that adding dapagliflozin 10 mg to standard therapy reduced HbA1c by 0.6% at 12 months without increasing urinary tract infections, acute rejection episodes, or graft loss 17.

Safety concerns specific to this population include the interaction between SGLT2 inhibitor-induced volume depletion and calcineurin inhibitor nephrotoxicity, as well as the theoretical risk of increased genitourinary infections in immunosuppressed patients. A multicenter RCT (DARLING, N=200) is recruiting to assess dapagliflozin's effect on graft function and glycemia in kidney transplant recipients 18. Until data mature, use in transplant patients should be limited to centers with transplant nephrology oversight.

Off-Label Use 7: Nephrotic Syndrome, Evidence Level C

SGLT2 inhibitors reduce proteinuria by lowering intraglomerular pressure, an effect demonstrated in the DAPA-CKD trial where dapagliflozin reduced urinary albumin-to-creatinine ratio (UACR) by 29.3% vs. placebo at 2 weeks, sustained through 24 months 19. The DAPA-CKD population included patients with IgA nephropathy and focal segmental glomerulosclerosis (FSGS), though the trial was not powered for subgroup analyses by glomerular disease type.

A 2024 open-label pilot study (N=26) in patients with steroid-resistant nephrotic syndrome added dapagliflozin 10 mg to renin-angiotensin blockade and found a median UACR reduction of 42% at 6 months 20. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 glomerular disease guideline now includes a conditional recommendation to consider SGLT2 inhibitors in proteinuric CKD regardless of diabetes status 21.

Safety Considerations Across All Off-Label Uses

Three risks recur in every off-label scenario. Euglycemic DKA is the most serious, occurring when glycosuria depletes glucose while ketogenesis continues unchecked. Risk is highest in type 1 diabetes, carbohydrate-restricted diets, perioperative fasting, and acute illness. Incidence in type 2 diabetes trials is low (0.1 to 0.3%) but not zero 22.

Genital mycotic infections affect 5 to 8% of patients across trials, with higher rates in women and uncircumcised men. These are treatable with topical antifungals and rarely lead to discontinuation 23.

Volume depletion and hypotension concern elderly patients and those on loop diuretics. The DAPA-HF protocol required investigators to reduce diuretic doses preemptively, a practice worth replicating in off-label prescribing 3.

Dr. Mikhail Kosiborod, cardiologist at Saint Luke's Mid America Heart Institute and DAPA-HF steering committee member, has noted: "The safety profile of dapagliflozin is well-characterized after more than 35,000 patient-years of randomized trial exposure. The challenge with off-label use is not the drug itself. It is ensuring that prescribers apply the same monitoring rigor outside the trial setting."

Evidence-Level Summary Table

| Off-Label Use | Evidence Level | Key Data Source | Estimated Effect Size | |---|---|---|---| | MASLD | B | Eriksson 2018 (N=84) | 13.4% liver fat reduction | | Type 1 diabetes | B (FDA rejected) | DEPICT-1/2 (N=1,646) | HbA1c -0.42%, DKA risk 4% | | Obesity (adjunct) | B-minus | Multiple post-hocs | 2 to 3 kg weight loss | | Gout/hyperuricemia | C-plus | DAPA-HF post-hoc | Uric acid -1.1 mg/dL | | ADPKD | C | Preclinical + ongoing RCT | TBD (STAGED-PKD) | | PTDM | C | Retrospective (N=80) | HbA1c -0.6% | | Nephrotic syndrome | C | DAPA-CKD subgroups | UACR -29.3% |

Patients considering any off-label use should have baseline eGFR ≥ 25 mL/min/1.73m², no history of DKA, and a clear plan for ketone monitoring during illness or fasting.